Lung Cancer

Liquid biopsy shows promise in Australian trial of NSCLC treatment

It’s a “no brainer” that liquid biopsy will eventually supersede tissue biopsy in guiding lung cancer treatment decisions, but more work is needed on the practical aspects of the procedure, early Australian experience suggests. A trial of liquid biopsy for detecting T790M mutations in patients with non-small cell lung cancer (NSCLC) showed it had advantages ...

Already a member?

Login to keep reading.

© 2021 the limbic